Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 562 across all filing types
Latest filing 2026-05-19 Capital/Financing Update
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 93% confidence The document is a press release announcing the closing of a $2 million shares-for-interest private placement, detailing the terms of the financing, share issuance price, number of shares, and changes to the company’s capital structure. This falls squarely under “Capital/Financing Update.” It is not a full financial report or certification, nor is it a share buyback. Hence, the correct classification is CAP.
2026-05-19 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a Chief Financial Officer’s certification (Form 52-109F2) of the issuer’s interim filings (interim financial report and interim MD&A) for the quarter ended March 31, 2026. It contains no actual financial statements or data but is an attestation letter under securities legislation. Per the Certification Rule, such officer certifications are classified as Regulatory Filings, not as the interim report itself.
2026-05-15 English
News release - English.pdf
Regulatory Filings
2026-05-11 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 95% confidence The document is a notification to Canadian Securities Regulatory Authorities about an upcoming Annual and Special Meeting of Security Holders for Resverlogix Corp. It includes details such as meeting type, record dates, meeting date, location, and proxy material delivery information. The document does not contain financial statements, management discussion, or detailed report content. It is a formal announcement related to a shareholder meeting rather than the meeting materials themselves or voting results. Given the content and length (1086 characters), it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting logistics without substantive report or voting results.
2026-04-20 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 95% confidence The document is a notice from Computershare to Canadian Securities Regulatory Authorities regarding an upcoming Annual and Special Meeting of Security Holders for Resverlogix Corp. It provides details such as meeting type, record dates, meeting date, and location. The document does not contain financial data, management discussion, voting results, or detailed meeting materials. It is a notification about the meeting rather than the meeting materials or results themselves. Given the short length (1086 characters) and the nature of the content, this fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about the meeting, not the actual AGM materials or voting results.
2026-04-20 English
News release - English.pdf
Report Publication Announcement Classification · 90% confidence The document is a news release announcing that Resverlogix has filed its audited financial statements, MD&A, certifications, and annual information form for the 2025 year end, as well as the revocation of an MCTO. It does not contain the actual filings themselves but is an announcement of their publication. It is brief (under 5,000 characters) and refers readers to SEDAR for the filings. This matches the “Report Publication Announcement (RPA)” category.
2026-04-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.